Literature DB >> 16283538

Modelling a spontaneously reported side effect by use of a Markov mixed-effects model.

Per-Henrik Zingmark1, Matts Kågedal, Mats O Karlsson.   

Abstract

AIMS: To present a method for analyzing side-effect data where change in severity is spontaneously reported during the experiment.
METHODS: A clinical study in 12 healthy volunteers aimed to investigate the concentration-response characteristics of a CNS-specific side-effect was conducted. After an open session where the subjects experienced the side-effect and where the individual pharmacokinetic parameters were evaluated they were randomized to a sequence of three different infusion rates of the drug in a double-blinded crossover way. The infusion rates were individualized to achieve the same target concentration in all subjects and different drug input rates were selected to mimic absorption profiles from different formulations. The occurrence of the specific side-effect and any subsequent change in severity was self-reported by the subjects. Severity was recorded as 0 = no side-effect, 1 = mild side-effect and 2 = moderate or severe side-effect.
RESULTS: The side-effect data were analyzed using a mixed-effects model for ordered categorical data with and without Markov elements. The former model estimated the probability of having a certain side-effect score conditioned on the preceding observation and drug exposure. The observed numbers of transitions between scores were from 0 -> 1: 24, from 0- > 2: 11, from 1 - >, 2: 23, from 2- > 1: 1, from 2- > 0: 32 and from 1 - >0: 2. The side-effect model consisted of an effect-compartment model with a tolerance compartment. The predictive performance of the Markov model was investigated by a posterior predictive check (PPC), where 100 datasets were simulated from the final model. Average number of the different transitions from the PPC was from 0 - > 1: 26, from 0 - > 2: 11, from 1 - > 2: 25, from 2 - >1: 1, from 2 - >0: 35 and from 1 - > 0: 1. A similar PPC for the model without Markov elements was at considerable disparity with the data.
CONCLUSION: This approach of incorporating Markov elements in an analysis of spontaneously reported categorical side-effect data could adequately predict the observed side-effect time course and could be considered in analyses of categorical data where dependence between observations is an issue.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16283538     DOI: 10.1007/s10928-005-0021-7

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.410


  14 in total

1.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Comput Methods Programs Biomed       Date:  1999-01       Impact factor: 5.428

Review 2.  Interchangeability and predictive performance of empirical tolerance models.

Authors:  M Gårdmark; L Brynne; M Hammarlund-Udenaes; M O Karlsson
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

3.  Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%.

Authors:  Catherijne A J Knibbe; Klaas P Zuideveld; Joost DeJongh; Paul F M Kuks; Leon P H J Aarts; Meindert Danhof
Journal:  Clin Pharmacol Ther       Date:  2002-12       Impact factor: 6.875

4.  Three new residual error models for population PK/PD analyses.

Authors:  M O Karlsson; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1995-12

5.  Pharmacodynamic model of tolerance: application to nicotine.

Authors:  H C Porchet; N L Benowitz; L B Sheiner
Journal:  J Pharmacol Exp Ther       Date:  1988-01       Impact factor: 4.030

6.  A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep.

Authors:  M O Karlsson; R C Schoemaker; B Kemp; A F Cohen; J M van Gerven; B Tuk; C C Peck; M Danhof
Journal:  Clin Pharmacol Ther       Date:  2000-08       Impact factor: 6.875

7.  Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.

Authors:  Y Yano; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

8.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

9.  A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data.

Authors:  L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1994-09       Impact factor: 6.875

10.  A Markov mixed effect regression model for drug compliance.

Authors:  P Girard; T F Blaschke; H Kastrissios; L B Sheiner
Journal:  Stat Med       Date:  1998-10-30       Impact factor: 2.373

View more
  18 in total

1.  Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamics.

Authors:  Radojka M Savic; France Mentré; Marc Lavielle
Journal:  AAPS J       Date:  2010-11-11       Impact factor: 4.009

2.  A Minimal Continuous-Time Markov Pharmacometric Model.

Authors:  Emilie Schindler; Mats O Karlsson
Journal:  AAPS J       Date:  2017-06-20       Impact factor: 4.009

Review 3.  Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.

Authors:  Karl Brendel; Céline Dartois; Emmanuelle Comets; Annabelle Lemenuel-Diot; Christian Laveille; Brigitte Tranchand; Pascal Girard; Céline M Laffont; France Mentré
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion.

Authors:  Hanna E Silber; Maria C Kjellsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-02-14       Impact factor: 2.745

Review 5.  The use of clinical utility assessments in early clinical development.

Authors:  Anis A Khan; Itay Perlstein; Rajesh Krishna
Journal:  AAPS J       Date:  2009-01-16       Impact factor: 4.009

Review 6.  Pharmacodynamic models for discrete data.

Authors:  Ines Paule; Pascal Girard; Gilles Freyer; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2012-12       Impact factor: 6.447

7.  Pharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measure.

Authors:  Mohamed A Kamal; David E Smith; Jack Cook; Douglas Feltner; Allen Moton; Daniele Ouellet
Journal:  J Pharm Sci       Date:  2010-08       Impact factor: 3.534

8.  The impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients.

Authors:  Olivia Campagne; Donald E Mager; Daniel Brazeau; Rocco C Venuto; Kathleen M Tornatore
Journal:  Br J Clin Pharmacol       Date:  2019-01-04       Impact factor: 4.335

9.  Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach.

Authors:  Martin Johnson; Magdalena Kozielska; Venkatesh Pilla Reddy; An Vermeulen; Hugh A Barton; Sarah Grimwood; Rik de Greef; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Pharm Res       Date:  2014-05-03       Impact factor: 4.200

10.  Joint modeling of dizziness, drowsiness, and dropout associated with pregabalin and placebo treatment of generalized anxiety disorder.

Authors:  Bill Frame; Raymond Miller; Matthew M Hutmacher
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-08       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.